STANDARD BIOTOOLS INC (LAB) Fundamental Analysis & Valuation

NASDAQ:LAB • US34385P1084

Current stock price

0.9237 USD
-0.05 (-5.5%)
At close:
0.94 USD
+0.02 (+1.76%)
After Hours:

This LAB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. LAB Profitability Analysis

1.1 Basic Checks

  • In the past year LAB has reported negative net income.
  • In the past year LAB has reported a negative cash flow from operations.
  • In the past 5 years LAB always reported negative net income.
  • In the past 5 years LAB always reported negative operating cash flow.
LAB Yearly Net Income VS EBIT VS OCF VS FCFLAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M

1.2 Ratios

  • The Return On Assets of LAB (-13.19%) is comparable to the rest of the industry.
  • LAB has a Return On Equity (-17.65%) which is in line with its industry peers.
Industry RankSector Rank
ROA -13.19%
ROE -17.65%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LAB Yearly ROA, ROE, ROICLAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150

1.3 Margins

  • With a Gross Margin value of 48.38%, LAB perfoms like the industry average, outperforming 56.14% of the companies in the same industry.
  • In the last couple of years the Gross Margin of LAB has declined.
  • The Profit Margin and Operating Margin are not available for LAB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 48.38%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.57%
GM growth 5Y-3.74%
LAB Yearly Profit, Operating, Gross MarginsLAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150 -200

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. LAB Health Analysis

2.1 Basic Checks

  • LAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • LAB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
LAB Yearly Shares OutstandingLAB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
LAB Yearly Total Debt VS Total AssetsLAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • Based on the Altman-Z score of -1.17, we must say that LAB is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -1.17, LAB is doing worse than 78.95% of the companies in the same industry.
  • A Debt/Equity ratio of 0.00 indicates that LAB is not too dependend on debt financing.
  • The Debt to Equity ratio of LAB (0.00) is better than 75.44% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.17
ROIC/WACCN/A
WACC10.94%
LAB Yearly LT Debt VS Equity VS FCFLAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

  • A Current Ratio of 4.19 indicates that LAB has no problem at all paying its short term obligations.
  • The Current ratio of LAB (4.19) is better than 70.18% of its industry peers.
  • A Quick Ratio of 4.01 indicates that LAB has no problem at all paying its short term obligations.
  • With a decent Quick ratio value of 4.01, LAB is doing good in the industry, outperforming 73.68% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.19
Quick Ratio 4.01
LAB Yearly Current Assets VS Current LiabilitesLAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. LAB Growth Analysis

3.1 Past

  • LAB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 63.64%, which is quite impressive.
  • LAB shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -39.29%.
  • Measured over the past years, LAB shows a decrease in Revenue. The Revenue has been decreasing by -9.18% on average per year.
EPS 1Y (TTM)63.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%155.56%
Revenue 1Y (TTM)-39.29%
Revenue growth 3Y-4.48%
Revenue growth 5Y-9.18%
Sales Q2Q%-49.07%

3.2 Future

  • Based on estimates for the next years, LAB will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.49% on average per year.
  • Based on estimates for the next years, LAB will show a small growth in Revenue. The Revenue will grow by 2.75% on average per year.
EPS Next Y19.2%
EPS Next 2Y15.91%
EPS Next 3Y15.49%
EPS Next 5YN/A
Revenue Next Year1.44%
Revenue Next 2Y2.03%
Revenue Next 3Y2.75%
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LAB Yearly Revenue VS EstimatesLAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M
LAB Yearly EPS VS EstimatesLAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2023 2024 2025 2026 2027 2028 -0.5 -1 -1.5 -2 -2.5

More info and screens

Find the best growth stocksShow best growing peers

0

4. LAB Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for LAB. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LAB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LAB Price Earnings VS Forward Price EarningsLAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LAB Per share dataLAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

  • A more expensive valuation may be justified as LAB's earnings are expected to grow with 15.49% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.91%
EPS Next 3Y15.49%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. LAB Dividend Analysis

5.1 Amount

  • No dividends for LAB!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

LAB Fundamentals: All Metrics, Ratios and Statistics

STANDARD BIOTOOLS INC

NASDAQ:LAB (4/16/2026, 8:00:02 PM)

After market: 0.94 +0.02 (+1.76%)

0.9237

-0.05 (-5.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-24
Earnings (Next)05-04
Inst Owners77.46%
Inst Owner Change-0.15%
Ins Owners2.4%
Ins Owner Change0.54%
Market Cap360.31M
Revenue(TTM)105.90M
Net Income(TTM)-74.90M
Analysts77.14
Price Target1.58 (71.05%)
Short Float %2.71%
Short Ratio4.87
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)54.35%
Min EPS beat(2)-62.02%
Max EPS beat(2)170.72%
EPS beat(4)2
Avg EPS beat(4)26.23%
Min EPS beat(4)-62.02%
Max EPS beat(4)170.72%
EPS beat(8)3
Avg EPS beat(8)-9.38%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)17.45%
Min Revenue beat(2)7.56%
Max Revenue beat(2)27.33%
Revenue beat(4)4
Avg Revenue beat(4)9.99%
Min Revenue beat(4)0.73%
Max Revenue beat(4)27.33%
Revenue beat(8)6
Avg Revenue beat(8)3.8%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-10%
EPS NQ rev (3m)-22.22%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.23%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.23%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.23%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.4
P/FCF N/A
P/OCF N/A
P/B 0.85
P/tB 0.85
EV/EBITDA N/A
EPS(TTM)-0.2
EYN/A
EPS(NY)-0.16
Fwd EYN/A
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)-0.19
OCFYN/A
SpS0.27
BVpS1.09
TBVpS1.09
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -13.19%
ROE -17.65%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 48.38%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.57%
GM growth 5Y-3.74%
F-Score3
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 75.64%
Cap/Sales 7.84%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.19
Quick Ratio 4.01
Altman-Z -1.17
F-Score3
WACC10.94%
ROIC/WACCN/A
Cap/Depr(3y)47.95%
Cap/Depr(5y)50.9%
Cap/Sales(3y)7.19%
Cap/Sales(5y)7.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)63.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%155.56%
EPS Next Y19.2%
EPS Next 2Y15.91%
EPS Next 3Y15.49%
EPS Next 5YN/A
Revenue 1Y (TTM)-39.29%
Revenue growth 3Y-4.48%
Revenue growth 5Y-9.18%
Sales Q2Q%-49.07%
Revenue Next Year1.44%
Revenue Next 2Y2.03%
Revenue Next 3Y2.75%
Revenue Next 5YN/A
EBIT growth 1Y26.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year75.27%
EBIT Next 3Y24.11%
EBIT Next 5YN/A
FCF growth 1Y45.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y48.18%
OCF growth 3YN/A
OCF growth 5YN/A

STANDARD BIOTOOLS INC / LAB Fundamental Analysis FAQ

What is the ChartMill fundamental rating of STANDARD BIOTOOLS INC (LAB) stock?

ChartMill assigns a fundamental rating of 2 / 10 to LAB.


What is the valuation status of STANDARD BIOTOOLS INC (LAB) stock?

ChartMill assigns a valuation rating of 0 / 10 to STANDARD BIOTOOLS INC (LAB). This can be considered as Overvalued.


What is the profitability of LAB stock?

STANDARD BIOTOOLS INC (LAB) has a profitability rating of 1 / 10.


How financially healthy is STANDARD BIOTOOLS INC?

The financial health rating of STANDARD BIOTOOLS INC (LAB) is 4 / 10.


What is the earnings growth outlook for STANDARD BIOTOOLS INC?

The Earnings per Share (EPS) of STANDARD BIOTOOLS INC (LAB) is expected to grow by 19.2% in the next year.